✨ Free AI Report
Tarsus Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Tarsus Pharmaceuticals, Inc.
Company Research

Tarsus Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Tarsus Pharmaceuticals, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Exceptional revenue momentum from XDEMVY with significant unmet medical need and expansion potential in eye care, offset by single-product concentration risk. XDEMVY delivered quarterly net sales of $119M in Q3 2025, up 147% year-over-year. The company has achieved rapid commercialization of the only approved treatment for Demodex blepharitis with.

What is Tarsus Pharmaceuticals, Inc.'s industry? Tarsus Pharmaceuticals, Inc. (tarsusrx.com) operates in Ophthalmology / Specialty Pharmaceuticals. AskCyborg classifies Tarsus Pharmaceuticals, Inc. under Ophthalmology / Specialty Pharmaceuticals in its company registry.

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on development and commercialization of therapeutic candidates for eye care, with lead product XDEMVY for treating Demodex blepharitis and...

8/ 10Strong

Cyborg Score thesis

Exceptional revenue momentum from XDEMVY with significant unmet medical need and expansion potential in eye care, offset by...

Read the full analyst-debate transcript →
Industry Ophthalmology / Specialty Pharmaceuticals
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Tarsus Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Tarsus Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Tarsus Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Tarsus Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Tarsus Pharmaceuticals, Inc. Overview

Pro stress-test →

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on development and commercialization of therapeutic candidates for eye care, with lead product XDEMVY for treating Demodex blepharitis and meibomian gland disease. The company has achieved exceptional commercial traction, reaching >$100M in quarterly sales within two years of launch.

Strategic Profile

Pro stress-test →

Expanded market access and international regulatory initiatives support top-line growth, while strong patient demand and favorable demographic trends drive sustainable revenue expansion through multi-product pipeline development. Beyond XDEMVY, the company is developing TP-04 for ocular rosacea, TP-05 for Lyme disease prophylaxis, and expanding lotilaner applications in infectious disease.

Competitive Landscape

Pro stress-test →

Tarsus operates in the ophthalmology market with XDEMVY as the only FDA-approved treatment for Demodex blepharitis. The broader eye care market includes competitors in dry eye disease (Allergan's Restasis, Bausch + Lomb's Xiidra) and related conditions. The company's first-to-market advantage in a significant unmet need provides a competitive moat, though pipeline efficacy and adoption rates will determine long-term competitive positioning.

Industry Context

Tarsus Pharmaceuticals, Inc. operates in Ophthalmology / Specialty Pharmaceuticals.

Key facts

Founded: 2016 · Headquarters: Irvine, California · Revenue: $119M quarterly (Q3 2025) · Market cap: $3.4B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Tarsus Pharmaceuticals, Inc..

  • TARS has passed $100M in quarterly XDEMVY sales milestone
  • Analyst upgrade to Strong Buy with $100/share 12-month price target driven by rapid XDEMVY commercialization
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Q3 2025 earnings report showing $119M in XDEMVY quarterly sales, up 147% YoY
  • August 2025Q2 2025 record product sales of $102.7M, up 152% YoY
  • +1 moreTrack every material event for Tarsus Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Tarsus Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

RestasisCyclosporine-based treatment for dry eye disease→XiidraLifitegrast-based treatment for dry eye disease→

Compare Tarsus Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Tarsus Pharmaceuticals, Inc. operates in Ophthalmology / Specialty Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Ophthalmology / Specialty Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Tarsus Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Tarsus Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Tarsus Pharmaceuticals, Inc. do this quarter?”
“Is Tarsus Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Tarsus Pharmaceuticals, Inc. do?+
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on development and commercialization of therapeutic candidates for eye care, with lead product XDEMVY for treating Demodex blepharitis and...
What is Tarsus Pharmaceuticals, Inc.'s Cyborg Score?+
Tarsus Pharmaceuticals, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Tarsus Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Restasis, Xiidra. The full competitive landscape is in the AskCyborg report.
How can I get the full Tarsus Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Tarsus Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Tarsus Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.